Biofrontera AG (ETR:B8FK)

Market Cap	15.50M
Revenue (ttm)	21.67M
Net Income (ttm)	-4.35M
Shares Out	6.08M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	501
Average Volume	1,631
Open	2.520
Previous Close	2.610
Day's Range	2.520 - 2.550
52-Week Range	2.080 - 7.730
Beta	0.16
RSI	55.07
Earnings Date	May 31, 2025

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 88
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: B8FK

Financial Performance

In 2024, Biofrontera AG's revenue was 21.67 million, a decrease of -32.81% compared to the previous year's 32.25 million. Losses were -4.35 million, 1078.9% more than in 2023.